Patents by Inventor Sakari Kauppinen

Sakari Kauppinen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense Oligonucleotides Targeting SARS-CoV-2
    Publication number: 20240102015
    Abstract: COVID-19 is treated with antisense oligonucleotides (ASOs) targeting SARS-CoV-2 viral RNAs or human ACE2 RNA.
    Type: Application
    Filed: January 19, 2023
    Publication date: March 28, 2024
    Applicants: The Regents of the University of California, Aalborg University
    Inventors: Anders Michael Naar, Chi Zhu, Sakari Kauppinen, Kasper Thystrup Karstensen
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATION OF LONG NONCODING RNAS
    Publication number: 20230348911
    Abstract: The present invention relates to noncoding RNAs as novel disease targets, and methods of modulating the activity of such ncRNA targets in patients. In particular, the invention relates to modulation of long non-coding RNAs, such as circular RNAs (circRNAs) or large intergenic noncoding RNAs (lincRNAs) in cancer using antisense oligonucleotides.
    Type: Application
    Filed: June 8, 2017
    Publication date: November 2, 2023
    Inventors: Sakari Kauppinen, Andreas Petri, Charlotte Albæk Thrue
  • INHIBITORS OF MICRO-RNA 22
    Publication number: 20230181613
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: October 12, 2022
    Publication date: June 15, 2023
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • Inhibitors of micro-RNA 22
    Patent number: 11499152
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 15, 2022
    Assignees: Beth Israel Deaconess Medical Center, Aalborg University
    Inventors: Pier Paolo Pandolfi, Riccardo Panella, Sakari Kauppinen, Andreas Petri
  • ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
    Publication number: 20220354888
    Abstract: The present invention provides antisense oligonucleotides directed against immune checkpoints and methods and compositions of using such antisense oligonucleotides for the treatment of cancer.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 10, 2022
    Inventors: Sakari Kauppinen, Andreas Petri, Charlotte Albæk Thrue
  • Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
    Publication number: 20220213477
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 7, 2022
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
    Patent number: 11236336
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: February 1, 2022
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20210071181
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the mIRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: October 1, 2020
    Publication date: March 11, 2021
    Inventors: Joacim ELMEN, Phil KEARNEY, Sakari KAUPPINEN
  • INHIBITORS OF MICRO-RNA 22
    Publication number: 20210017521
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
    Publication number: 20200362342
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: March 24, 2020
    Publication date: November 19, 2020
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Antisense oligomers targeting HOXB-AS3 long non-coding RNA
    Patent number: 10787665
    Abstract: The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: September 29, 2020
    Assignees: Ohio State Innovation Foundation, Aalborg University
    Inventors: Ramiro Garzon, Adrienne Dorrance, Dimitrios Papaioannou, Robert Lee, Sakari Kauppinen, Andreas Petri, Charlotte AlbÆk Thrue
  • Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
    Patent number: 10626395
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 21, 2020
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • TARGETING HUMAN SATELLITE II (HSATII)
    Publication number: 20200017856
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.
    Type: Application
    Filed: April 24, 2019
    Publication date: January 16, 2020
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Micromirs
    Patent number: 10450564
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 22, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
    Publication number: 20190270993
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Application
    Filed: September 18, 2017
    Publication date: September 5, 2019
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • ANTISENSE OLIGOMERS TARGETING HOXB-AS3 LONG NON-CODING RNA
    Publication number: 20190256848
    Abstract: The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.
    Type: Application
    Filed: November 3, 2017
    Publication date: August 22, 2019
    Inventors: Ramiro GARZON, Adrienne DORRANCE, Dimitrios PAPAIOANNOU, Robert LEE, Sakari KAUPPINEN, Andreas PETRI, Charlotte ALBÆK THRUE
  • Targeting human satellite II (HSATII)
    Patent number: 10301624
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Pharmaceutical Composition
    Publication number: 20190071672
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 7, 2019
    Inventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen
  • MICROMIRS
    Publication number: 20180201928
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 19, 2018
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Pharmaceutical Composition
    Publication number: 20180195062
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 12, 2018
    Inventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen